Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Market Cap	231.72B +136.3%
Revenue (ttm)	34.99M -30.0%
Net Income	-488.25M
EPS	-0.32
Shares Out	1.55B
PE Ratio	n/a
Forward PE	62.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,280,843
Average Volume	7,281,932
Open	147.00
Previous Close	149.50
Day's Range	140.00 - 147.50
52-Week Range	54.10 - 277.00
Beta	0.55
RSI	41.09
Earnings Date	Feb 6, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6919

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.